BOSTON, November 12, 2025 — Leads & Copy — BPGbio, Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has appointed John Dvor as Executive Vice President, Corporate Development.
Dvor will lead the company’s corporate growth strategy, including commercialization, capital formation, mergers and acquisitions, and joint ventures, to advance its therapeutic pipeline and AI platform assets.
Dvor has over two decades of experience in venture capital, biotechnology, and global finance. He was previously Managing Director at Miraki Innovation, a $175 million life sciences venture fund spun out of Massachusetts General Hospital. He also co-founded Tufts Health Ventures, a $250 million corporate VC fund at Tufts Health Plan, and serves as Venture Partner at C10 Labs, an AI-first venture fund spun out of MIT. His past transactions include Iora Health (acquired for $2.1 billion), SSI Innovations (IPO, $1.3 billion), and BOA Biomedical.
BPGbio is nearing commercialization of its clinical programs and AI-validated assets. The company’s NAi® Interrogative Biology® platform, built on a large clinically annotated biobank and powered by causal AI, has identified over 250 novel drug targets across 15 AI-driven disease models. Approximately 50 of these targets have been experimentally validated across oncology, neurology, and rare diseases.
BPGbio recently completed enrollment in its Phase 2b glioblastoma (GBM) trial and is planning a registrational study in Primary CoQ10 Deficiency (PCQD), a rare pediatric mitochondrial disorder. The company also has a preclinical portfolio in E2-based targeted protein degradation and partnerships with Oxford University, Stanford University, the U.S. Department of Defense, and Uniformed Services University of the Health Sciences.
Niven R. Narain, Ph.D., President and CEO of BPGbio, said that Dvor’s experience in building, financing, and creating successful exits for health companies will be instrumental in unlocking the potential of the company’s NAi platform and clinical assets through partnerships, licensing, and global growth.
John Dvor stated that BPGbio’s approach to AI drug development, combined with its clinical programs and causal discovery engine, makes it a compelling opportunity. He added that the pharmaceutical industry’s average investment of $6 billion per new drug is unsustainable, and BPGbio’s model improves efficiency, reduces risk, and delivers biologically validated targets.
Dvor previously held senior executive roles at miR Scientific, Pluri Biotech, and ReMed Life Sciences, and advised global family offices including the Aga Khan Foundation, Millhouse Capital, and Helge Capital. He is a U.S. Marine Corps veteran and a Harvard University graduate.
John Dvor can be contacted via Media@BPGbio.com
BPGbio is focused on mitochondrial biology and protein homeostasis. The company has a pipeline of AI-developed therapeutics in oncology, rare disease, and neurology, including several in late-stage clinical trials. BPGbio’s NAi Interrogative Biology Platform is protected by over 500 U.S. and international patents and has access to a large clinically annotated biobank and the Frontier supercomputer.
For more information, visit www.bpgbio.com.
Source: BPGbio
